Literature DB >> 17512261

Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta.

Omar F Carrasco1, Horacio Vidrio.   

Abstract

The triterpene saponin escin is the active component of the extract of seeds of Aesculus hippocastanum used in the treatment of chronic venous insufficiency. Escin is also used experimentally to increase membrane permeability in isolated cells. Since endothelial dysfunction is postulated to be involved in venous insufficiency, the possible endothelium-protectant effect of escin was explored in rat aortic rings, a model widely used to study such effects with cardiovascular agents. Escin enhanced endothelium-dependent relaxation induced by acetylcholine when such relaxation had been reduced by exposure to the superoxide ion generator pyrogallol. This effect was attributed to enhanced nitric oxide production by endothelial nitric oxide synthase, a calcium-dependent enzyme, activated by the increased endothelial cell permeability to calcium induced by escin. Another effect of escin thought to contribute to its therapeutic activity is its ability to produce venous contraction. The compound was found to induce concentration-related contraction also in rat aortic rings. This response was partially inhibited by removal of the endothelium or by preincubation with indomethacin, and was completely abolished by incubation in a calcium-free perfusion fluid. Contraction was considered to be due mainly to the aforementioned effect on calcium permeability, with some mediation by release of endothelial vasoconstrictor prostanoids. It was concluded that, in rat aorta, escin possesses an endothelium-protectant action and a direct contractile effect. The former could contribute to its beneficial effect in the treatment of venous insufficiency, while the latter could constitute a limiting side effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512261     DOI: 10.1016/j.vph.2007.04.003

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  12 in total

1.  Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  J Vasc Surg       Date:  2011-04-16       Impact factor: 4.268

2.  Protective effects of the preconditioning with different doses of sodium aescinate on tourniquet-induced ischemic reperfusion.

Authors:  Guang Yang; Su-Yang Cui; Li-Bing Huang
Journal:  Chin J Integr Med       Date:  2011-07-03       Impact factor: 1.978

Review 3.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

4.  Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation.

Authors:  Ines Lindner; Christiane Meier; Angelika Url; Hermann Unger; Andreas Grassauer; Eva Prieschl-Grassauer; Petra Doerfler
Journal:  BMC Immunol       Date:  2010-05-21       Impact factor: 3.615

5.  Effect of Cymbopogon citratus and Citral on Vascular Smooth Muscle of the Isolated Thoracic Rat Aorta.

Authors:  R Chitra Devi; S M Sim; R Ismail
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-22       Impact factor: 2.629

6.  Endothelia-Targeting Protection by Escin in Decompression Sickness Rats.

Authors:  Kun Zhang; Zhongxin Jiang; Xiaowei Ning; Xuhua Yu; Jiajun Xu; Peter Buzzacott; Weigang Xu
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

7.  Mechanisms of Lower Extremity Vein Dysfunction in Chronic Venous Disease and Implications in Management of Varicose Veins.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Vessel Plus       Date:  2021-05-29

8.  Anti-inflammatory effects of escin are correlated with the glucocorticoid receptor/NF-κB signaling pathway, but not the COX/PGF2α signaling pathway.

Authors:  Hongsheng Wang; Leiming Zhang; Na Jiang; Zhenhua Wang; Yating Chong; Fenghua Fu
Journal:  Exp Ther Med       Date:  2013-05-22       Impact factor: 2.447

Review 9.  Male infertility: lifestyle factors and holistic, complementary, and alternative therapies.

Authors:  David F Yao; Jesse N Mills
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

Review 10.  Phytotherapy: emerging therapeutic option in urologic disease.

Authors:  Sae Woong Kim
Journal:  Transl Androl Urol       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.